FY2028 EPS Estimates for Haemonetics Increased by Analyst

Haemonetics Corporation (NYSE:HAE) – Zacks Research upped their FY2028 EPS estimates for Haemonetics in a note issued to investors on Monday, July 7th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $6.03 per share for the year, up from their previous estimate of $6.02. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share.

Several other analysts also recently weighed in on the stock. Raymond James Financial reissued a “strong-buy” rating and set a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Baird R W upgraded shares of Haemonetics to a “strong-buy” rating in a research note on Wednesday, June 25th. JMP Securities reissued a “market outperform” rating and set a $100.00 price objective on shares of Haemonetics in a report on Tuesday, May 20th. Wall Street Zen downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Finally, Robert W. Baird began coverage on Haemonetics in a research report on Thursday, June 26th. They set an “outperform” rating and a $87.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $97.30.

Haemonetics Stock Performance

HAE opened at $78.35 on Thursday. The company has a market cap of $3.76 billion, a P/E ratio of 23.67, a price-to-earnings-growth ratio of 1.26 and a beta of 0.39. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. The firm’s 50-day moving average price is $70.50 and its 200-day moving average price is $68.06. Haemonetics has a 52-week low of $55.30 and a 52-week high of $94.99.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The firm had revenue of $330.60 million during the quarter, compared to analysts’ expectations of $329.38 million. During the same quarter last year, the firm earned $0.90 EPS. The business’s quarterly revenue was down 3.5% on a year-over-year basis.

Hedge Funds Weigh In On Haemonetics

A number of institutional investors have recently modified their holdings of the stock. Norges Bank acquired a new stake in Haemonetics during the fourth quarter worth about $32,803,000. Voya Investment Management LLC lifted its holdings in Haemonetics by 820.5% in the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier’s stock valued at $24,748,000 after acquiring an additional 282,521 shares during the period. Envestnet Asset Management Inc. boosted its position in Haemonetics by 9.6% in the 4th quarter. Envestnet Asset Management Inc. now owns 48,068 shares of the medical instruments supplier’s stock worth $3,753,000 after purchasing an additional 4,217 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Haemonetics by 7.3% during the 4th quarter. Stifel Financial Corp now owns 14,776 shares of the medical instruments supplier’s stock worth $1,154,000 after purchasing an additional 1,006 shares during the period. Finally, Natixis Advisors LLC purchased a new position in shares of Haemonetics during the 4th quarter valued at approximately $1,194,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.